Lyon manufacturing facility returns to the Vectura Group
![](/46/pdcnewsitem/04/15/54/Vectura.jpg)
The facility currently manufactures seven oral products for the Group's partners.
Vectura Group has confirmed that, as expected, the lease of its manufacturing facility and oral product business in Saint-Quentin-Fallavier, Lyon, France to Aenova France expired on 30 June 2016. The facility transferred back to the Group upon expiry.
The facility currently manufactures seven oral products for the Group's partners. Five products use the Geomatrix family of technologies: Diclofenac-ratiopharm-uno, Coruno, ZYFLO CR, Madopar DR/Prolopa and Sular, whilst Lodotra/RAYOS uses the Geoclock chronotechnology. The facility also manufactures one other oral product, Triglide, based on the Group's solubilisation technology. In addition, there are currently a number of pipeline projects in development, including the first complex oral generic under the Group's strategic partnership with Hikma Pharmaceuticals. The facility has cGMP status, with approvals from the European Medicines Agency, the FDA, ANVISA (Brazil) and KFDA (South Korea) amongst others.
A number of initiatives are underway to maximise the value of the facility now that it has returned to the Group's control, leveraging proven capabilities in multilayer tableting, oral technology innovation and the high quality manufacturing capacity at the Lyon site.
David Lescuyer, Executive Vice President, Oral Business, commented: "We are very pleased that the Lyon facility returns to the Group at this exciting time. We have a strong high quality base with the return of the facility and we are confident of growing the business and creating future value by working with existing and new partners and leveraging our proven innovation and technology."
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance